Archives of Endocrinology Metabolism最新文献

{"title":"Pharmacologic Treatment of Obesity in adults and its impact on comorbidities: 2024 Update and Position Statement of Specialists from the Brazilian Association for the Study of Obesity and Metabolic Syndrome (Abeso) and the Brazilian Society of Endocrinology and Metabolism (SBEM).","authors":"Rodrigo O Moreira, Cynthia M Valerio, Alexandre Hohl, Cristiane Moulin, Fábio Moura, Fábio R Trujilho, Fernando Gerchman, Livia L Correa, Marcio C Mancini, Maria Edna Melo, Rodrigo N Lamounier, Simone van de Sande-Lee, Thaísa D G Trujilho, Paulo A C Miranda, Bruno Halpern","doi":"10.20945/2359-4292-2024-0422","DOIUrl":"10.20945/2359-4292-2024-0422","url":null,"abstract":"<p><p>Pharmacological treatment of obesity is passing through many changes in the last decades; different agents have been approved, and newer options are leaning towards higher efficacy and a more favourable safety profile; however, medications approved for a longer time are still available and useful for many patients. This document is an 2024 Update Position Statement of Specialists from the Brazilian Association for the Study of Obesity and Metabolic Syndrome (Abeso) and the Brazilian Society of Endocrinology and Metabolism (SBEM), with the aim of reviewing all the approved medications for the management of obesity in Brazil (sibutramine, orlistat, liraglutide, semaglutide and bupropion/naltrexone fixed dose), with the addition of tirzepatide, that is approved in other countries and likely approved soon in Brazil. The review is focused on efficacy, safety profile and the impact of drugs (based on existing studies) on different comorbidities.</p>","PeriodicalId":54303,"journal":{"name":"Archives of Endocrinology Metabolism","volume":"68 ","pages":"e240422"},"PeriodicalIF":1.6,"publicationDate":"2024-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11634287/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142815024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of tributyltin on placental and reproductive abnormalities in offspring.","authors":"Charles S da Costa, Hanin Alahmadi, Genoa R Warner, Maria Tereza Nunes, Glaecir Roseni Mundstock Dias, Leandro Miranda-Alves, Jones B Graceli","doi":"10.20945/2359-4292-2024-0186","DOIUrl":"10.20945/2359-4292-2024-0186","url":null,"abstract":"<p><p>Tributyltin (TBT) is an organotin compound and a common persistent environmental pollutant with endocrine-disrupting chemical (EDC) actions. It can accumulate in the environment at various concentrations throughout the food chain in the ecosystem, posing a risk to human health, especially during critical periods such as gestation and fetal and offspring development. In this review, we report the results of studies describing the consequences of TBT exposure on placental and reproductive parameters in offspring of both sexes. Results from <i>in vivo</i> and <i>in vitro</i> studies clearly indicate that TBT causes adverse effects on placental development and reproductive parameters in offspring. However, substantial knowledge gaps remain in the literature, requiring further research to better understand the mechanisms behind TBT effects on placental and reproductive disruption in offspring.</p>","PeriodicalId":54303,"journal":{"name":"Archives of Endocrinology Metabolism","volume":"68 Spec","pages":"e240186"},"PeriodicalIF":1.6,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11771755/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143059918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between the aromatase (<i>CYP19A1</i>) gene variant rs10046 and cardiovascular risk in postmenopausal women.","authors":"Betânia Rodrigues Dos Santos, Gislaine Casanova, Thais Rasia da Silva, Karen Oppermann, Poli Mara Spritzer","doi":"10.20945/2359-4292-2024-0087","DOIUrl":"10.20945/2359-4292-2024-0087","url":null,"abstract":"<p><strong>Objective: </strong>To assess the genotypic and allelic distribution of the rs10046 polymorphism in the <i>CYP19A1</i> gene and evaluate whether this aromatase gene variant is associated with cardiovascular risk in postmenopausal women.</p><p><strong>Materials and methods: </strong>This cross-sectional study analyzed repository-stored samples from 370 postmenopausal women aged 44-72 years. Clinical, metabolic, and hormonal data were collected. The patients' estimated 10-year atherosclerotic cardiovascular disease (ASCVD) risk was calculated using the ASCVD Risk Estimator Plus, as recommended by the American College of Cardiology/American Heart Association. Genotyping of the rs10046 polymorphism of the <i>CYP19A1</i> gene was carried out using real-time polymerase chain reaction with allelic discrimination assays.</p><p><strong>Results: </strong>The participants had a mean age of 56.07 ± 5.58 years and a mean body mass index (BMI) of 27.73 ± 5.41 kg/m². The 10-year ASCVD risk was estimated to be low, borderline, intermediate, and high in 64.7%, 12.8%, 19.8%, and 2.7% of the participants, respectively. The CC genotype of the rs10046 polymorphism was associated with low estradiol levels (p = 0.003) and high ASCVD scores (p = 0.014). In a multivariate model, age (p < 0.001) and CC genotype (p = 0.021) were independently associated with higher ASCVD risk.</p><p><strong>Conclusion: </strong>The present study found that the CC genotype of the rs10046 polymorphism in the <i>CYP19A1</i> gene is associated with low estradiol levels and an increased ASCVD risk. Additionally, the results indicated that, among postmenopausal women, age and the CC genotype of rs10046 were associated with a high prevalence of ASCVD risk, independent of BMI.</p>","PeriodicalId":54303,"journal":{"name":"Archives of Endocrinology Metabolism","volume":"68 Spec","pages":"e240087"},"PeriodicalIF":1.6,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11771756/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143061513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prenatal exposure to nitrate alters uterine morphology and gene expression in adult female F1 generation rats.","authors":"André Gilberto Cassiani, Thiago Pinheiro Arrais Aloia, Érica Kássia Sousa-Vidal, Sérgio Podgaec, Carla de Azevedo Piccinato, Caroline Serrano-Nascimento","doi":"10.20945/2359-4292-2024-0085","DOIUrl":"10.20945/2359-4292-2024-0085","url":null,"abstract":"<p><strong>Objective: </strong>Nitrate is ubiquitously found in the environment and is one of the main components of nitrogen fertilizers. Previous studies have shown that nitrate disrupts the reproductive system in aquatic animals, but no study has evaluated the impact of nitrate exposure on the uterus in mammals. This study aimed to evaluate the impact of maternal exposure to nitrate during the prenatal period on uterine morphology and gene expression in adult female F1 rats.</p><p><strong>Materials and methods: </strong>Pregnant Wistar rats were either treated with sodium nitrate 20 mg/L or 50 mg/L dissolved in drinking water from the first day of pregnancy until the birth of the offspring or were left untreated. On postnatal day 90, the uteri of female offspring rats were collected for histological and gene expression analyses. Morphometric analyses of the uterine photomicrographs were performed to determine the thickness of the layers of the uterine wall (endometrium, myometrium, and perimetrium) and the number of endometrial glands.</p><p><strong>Results: </strong>The highest nitrate dose increased the myometrial thickness of the exposed female rats. Treatment with both nitrate doses reduced the number of endometrial glands compared with no treatment. Additionally, nitrate treatment significantly increased the expression of estrogen receptors and reduced the expression of progesterone receptors in the uterus.</p><p><strong>Conclusion: </strong>Our results strongly suggest that prenatal exposure to nitrate programs gene expression and alters the uterine morphology in female F1 rats, potentially increasing their susceptibility to developing uterine diseases during adulthood.</p>","PeriodicalId":54303,"journal":{"name":"Archives of Endocrinology Metabolism","volume":"68 Spec","pages":"e240085"},"PeriodicalIF":1.6,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11771761/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143061055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fertility induction associated with improved peripheral reproductive parameters in male <i>Prop1^df/df</i> mice subjected to GH and levothyroxine replacement.","authors":"Bruna Viscardi Azevedo, Juliana Moreira Marques, Nicholas Trigueiro, Victor Yuji Yariwake, Mariana Matera Veras, Leticia Kaory Tamashiro, Robison Cruz, Luciani R Silveira de Carvalho","doi":"10.20945/2359-4292-2024-0086","DOIUrl":"10.20945/2359-4292-2024-0086","url":null,"abstract":"<p><strong>Objective: </strong>The aim of this study was to characterize the parameters of reproductive anatomy and pituitary hormone expression levels in ames dwarf mice <i>(Prop1</i> ^df/df).</p><p><strong>Materials and methods: </strong>Male <i>Prop1^df/df</i> mice aged 30 days received daily intraperitoneal injections of recombinant human GH and levothyroxine three times weekly for 60 days. The sexual maturation of these animals was compared with that of their wild-type (<i>Prop</i> ^+/+) and untreated (<i>Prop1^df/df</i> ) siblings.</p><p><strong>Results: </strong>The <i>Prop1^df/df</i> treated group developed sexual maturation 2 weeks later than the <i>Prop</i> ^+/+ group and presented an increase in testicular weight, complete spermatogenesis, and enhanced LH and FSH expression. The <i>Prop1^df/df</i> untreated group had low FSH expression and no offspring; most animals in this group did not develop sexual maturation during the study period.</p><p><strong>Conclusion: </strong>Replacement with GH and levothyroxine appeared to play a crucial role in restoring peripheral reproductive parameters and increasing pituitary hormone expression in <i>Prop1^df/df</i> mice.</p>","PeriodicalId":54303,"journal":{"name":"Archives of Endocrinology Metabolism","volume":"68 Spec","pages":"e240086"},"PeriodicalIF":1.6,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11771760/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143060777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pyriproxyfen, villain or good guy? A brief review.","authors":"Andressa Pereira Cabral, Fabrício Pereira Dos Santos Maia, D'Angelo Carlo Magliano, Jones Bernardes Graceli, Paula Soares, Eduardo Andrés Rios Morris, Leandro Miranda-Alves","doi":"10.20945/2359-4292-2024-0154","DOIUrl":"10.20945/2359-4292-2024-0154","url":null,"abstract":"<p><p>Pyriproxyfen (PPF) acts as a juvenile growth regulator, interfering with normal metamorphosis and blocking the development of insects into adulthood. Although the World Health Organization (WHO) considers the use of PPF at a concentration of 0.01 mg/L as unlikely to pose health risks, recent studies have unveiled potential risks associated with PPF exposure to non-target organisms. Exposure to PPF disrupts insect development primarily by mimicking juvenile hormones; therefore, concerns linger over its impact on unintended species. Studies have highlighted the adverse effects of PPF on aquatic invertebrates, fish, and amphibians and revealed mortality and developmental abnormalities in non-target mosquito species exposed to PPF-treated water. Moreover, PPF may act as an endocrine disruptor, interfering with hormonal pathways crucial for growth, reproduction, and behavior in exposed organisms. Amphibians, for instance, display altered reproductive physiology and developmental abnormalities due to disruptions in endocrine signaling pathways caused by PPF. The ecological ramifications of PPF extend beyond direct toxicity to non-target species. Indirect effects include shifts in food web dynamics and ecosystem functioning. Reductions in insect populations, induced by PPF, can disrupt food availability for higher trophic levels, potentially destabilizing community structure and ecosystem equilibrium. Given mounting evidence of unintended consequences, robust risk assessment and regulatory oversight are imperative. Accurate classification of PPF by regulatory bodies is essential to balancing its role in disease control and pest management benefits with the need to safeguard non-target species and maintain ecosystem health. Future research must prioritize comprehensive assessments of PPF's ecological impact across various habitats and taxa to inform evidence-based policymaking.</p>","PeriodicalId":54303,"journal":{"name":"Archives of Endocrinology Metabolism","volume":"68 Spec","pages":"e240154"},"PeriodicalIF":1.6,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11771759/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143060995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Basic, translational, and clinical research - a short reflection.","authors":"Peter A Kopp","doi":"10.20945/2359-4292-2024-0400","DOIUrl":"10.20945/2359-4292-2024-0400","url":null,"abstract":"","PeriodicalId":54303,"journal":{"name":"Archives of Endocrinology Metabolism","volume":"68 Spec","pages":"e240400"},"PeriodicalIF":1.6,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11771749/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143061517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Institutional case volumes of thyroidectomies in Brazil and the impact of the COVID-19 pandemic: insights from a national database.","authors":"Leonardo Barbi Walter, Wallace Klein Schwengber, Anita Lavarda Scheinpflug, Andre Borsatto Zanella, Rafael Selbach Scheffel, Ana Luiza Maia, Jose Miguel Dora","doi":"10.20945/2359-4292-2024-0152","DOIUrl":"https://doi.org/10.20945/2359-4292-2024-0152","url":null,"abstract":"<p><strong>Introduction: </strong>Providing widespread access to thyroidectomies while consolidating services in high-volume centers is a significant challenge in healthcare. In this context, from a national perspective, we aimed to analyze the impact of the COVID-19 pandemic on the institutional case volumes of thyroid surgery in Brazil.</p><p><strong>Material and methods: </strong>We analyzed retrospective thyroidectomy data from the Department of Informatics of the Unified Health System (Datasus), stratifying institutions into low-volume, intermediate-volume, and high-volume centers (<10, 10-100, and >100 thyroidectomies/year, respectively). We assessed the differences in absolute numbers and percentages of thyroidectomies performed during the pandemic years (2020-2022) compared with the pre-pandemic year (2019). Differences in the proportion of institutions based on case volumes from 2019 to 2022 were assessed using Cochran's Q test.</p><p><strong>Results and discussion: </strong>In 2019, 556 Brazilian institutions performed 15,331 thyroidectomies. Of these, 46.4% were categorized as low-volume, 48.4% as intermediate-volume, and 5.2% as high-volume institutions, accounting for 5.5%, 61.4%, and 33.1% of the thyroidectomies, respectively. Compared with 2019, the volume of thyroidectomies was lower by 41.2% in 2020, 37.0% in 2021, and 12.8% in 2022. When analyzing the proportions of institutions that maintained their pre-pandemic case volume in the first pandemic year, the intermediate and high-volume institutions experienced reductions of 34.9% (p < 0.001) and 58.6% (p < 0.001), respectively, while low-volume institutions presented a 4.3% reduction (p = 0.081).</p><p><strong>Conclusion: </strong>The COVID-19 pandemic disrupted the landscape of thyroidectomies in Brazil, particularly affecting intermediate-volume and high-volume institutions, while low-volume institutions showed greater resilience.</p>","PeriodicalId":54303,"journal":{"name":"Archives of Endocrinology Metabolism","volume":"68 ","pages":"e240152"},"PeriodicalIF":1.6,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11554365/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142632479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PTH immunoassay interference: differential diagnosis with normocalcemic primary hyperparathyroidism?","authors":"Monique Nakayama Ohe, Roberto Massao Takimoto, Claudia M Aparecida de Francischi Ferrer, Jose Viana Lima, Rosa Paula Biscolla, José Gilberto Henriques Vieira, Maria Izabel Chiamolera","doi":"10.20945/2359-4292-2023-0315","DOIUrl":"https://doi.org/10.20945/2359-4292-2023-0315","url":null,"abstract":"<p><p>The main diagnostic dilemma in normocalcemic hyperparathyroidism is differentiating this condition from secondary hyperparathyroidism and other causes of elevated parathyroid hormone (PTH) levels in eucalcemic patients, including potential assay interferences. Despite the analytical sensitivity of immunoassays, they may lack adequate accuracy due to several analytical interferences, such as the presence of heterophilic antibodies. Immunoassays for PTH measurement use the immunometric \"sandwich\" technique, and only a few cases of interference with this assay have been reported to date. We describe herein two patients in whom PTH immunoassay interference was demonstrated. Both patients presented high serum PTH levels, measured using a second-generation Roche electrochemiluminescence assay (ECLIA; Elecsys Roche, Germany), and normocalcemia. When immunoassay interference was suspected, PTH measurements were repeated using a different analytical platform, the 1-84 PTH third-generation Roche Elecsys ECLIA, resulting in normal levels. We subsequently performed serial dilutions using normal mouse serum with the second-generation ECLIA and found no linearity, indicating the presence of interference in both patients. Immunoassay interference may lead to misinterpretation of a patient's results by the laboratory and incorrect treatment planning by the attending physician. Despite its rarity, the presence of interferences in the PTH immunoassay resulting in falsely high PTH levels should be considered when the laboratory result does not match the patient's clinical presentation, thus preventing erroneous diagnoses and unnecessary therapeutic procedures.</p>","PeriodicalId":54303,"journal":{"name":"Archives of Endocrinology Metabolism","volume":"68 ","pages":"e230315"},"PeriodicalIF":1.6,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11554362/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142632495","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Single zoledronic acid infusion as a cause of acute kidney impairment requiring dialysis in two patients with osteoporosis.","authors":"Djordje Marina, Charlotte Ejersted, Kristine Hommel, Peter Schwarz","doi":"10.20945/2359-4292-2024-0159","DOIUrl":"https://doi.org/10.20945/2359-4292-2024-0159","url":null,"abstract":"<p><p>Zoledronic acid is a widely used bisphosphonate for treating osteoporosis and hypercalcemia related to malignancy. It is also used to prevent bone loss induced by cancer treatment and bone metastases in various cancer types. Zoledronic acid is safe for most patients and is generally not associated with severe side effects. However, there have been reports of acute kidney impairment occurring after administration of intravenous zoledronic acid, mostly in patients with cancer (who received a high cumulative dose of this medication) or preexisting kidney impairment, and in patients with a history of nephrotoxic treatment. We report herein the cases of two patients without history of cancer, who developed dialysis-requiring acute kidney impairment after a single administration of intravenous zoledronic acid. None of the patients had previously used nephrotoxic medications, and one of them had a normal kidney function before zoledronic acid treatment. To the best of our knowledge, this report describes the first case of acute kidney impairment in a patient without risk factors. The findings of this report show that acute kidney impairment following intravenous zoledronic acid treatment can also occur in low-risk patients, highlighting the need for monitoring kidney function in all patients receiving this treatment.</p>","PeriodicalId":54303,"journal":{"name":"Archives of Endocrinology Metabolism","volume":"68 ","pages":"e240159"},"PeriodicalIF":1.6,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11554369/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142632523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}